Boc 氨基已酸-Osu | 51513-80-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: Boc 氨基已酸-Osu
• 中文别名: 6-(叔丁氧羰基-氨基)己酸N-琥珀酰亚胺基酯；Boc氨基已酸-Osu；6-(BOC-氨基)己酸N-琥珀酰亚胺酯；6-(BOC-氨基)羊油酸N-琥珀酰亚胺酯
• 英文名称: N-Boc-6-aminohexanoic acid N-hydroxysuccinimide ester
• 英文别名: 2,5-dioxopyrrolidin-1-yl 6-((tert-butoxycarbonyl)amino)hexanoate；Boc-6-Ahx-OSu；(2,5-dioxopyrrolidin-1-yl) 6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate
• CAS: 51513-80-5
• 化学式: C₁₅H₂₄N₂O₆
• 分子量: 328.365
• InChiKey: TYJPSIQEEXOQLC-UHFFFAOYSA-N

物化性质

• 熔点：
  86-90 °C
• 密度：
  1.20±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R38
• 海关编码：
  2925190090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H315
• 危险性防范说明：
  P280
• 储存条件：
  -20°C下保存在惰性气体中，并应避免光照、湿气和加热以防止分解。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Boc-6-Ahx-OSu
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 51513-80-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Skin irritation (Category 2), H315
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 6-(Boc-amino)hexanoic acid N-succinimidyl ester
6-(Boc-amino)caproic acid N-succinimidyl ester
Formula : C15H24N2O6
Molecular Weight : 328,36 g/mol
CAS-No. : 51513-80-5
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
Boc-6-Ahx-OSu
CAS-No. 51513-80-5 Skin Irrit. 2; H315 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
Boc-6-Ahx-OSu
CAS-No. 51513-80-5 Xi, R38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Keep in a dry place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 86 - 90 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,117
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. The
preceding data, or interpretation of data, was determined using Quantitative Structure Activity Relationship
(QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6-(N-保护基乙酰氧甲氧羰基)己酸N-羟基琥珀酰亚胺酯是一种蛋白质交联剂。

反应信息

• 作为反应物：
  描述：

  Boc 氨基已酸-Osu 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 19.02h， 生成
  参考文献：
  名称：

  体内可用的近红外萤火虫萤光素的合理设计和开发

  摘要：

  发光：利用分子内生物发光共振能量转移（BRET）为体内可用的近红外发射萤火虫荧光素开发了一种新的合理设计策略。可以通过选择BRET受体自由调节发射波长，并且可以在不需要荧光素酶操作的情况下在活细胞和小鼠中检测NIR生物发光。

  DOI：

  10.1002/anie.201205151
• 作为产物：
  描述：

  碳酸二叔丁酯 在 sodium hydroxide 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 反应 24.0h， 生成 Boc 氨基已酸-Osu
  参考文献：
  名称：

  Benextramine-neuropeptide Y受体的相互作用：苄基部分对[3H] neuropeptide Y置换活性的贡献。

  摘要：

  使用溶液相肽合成方法合成了N，N'-双[6-[（[2-甲氧基苄基）氨基]己-1-基]胱胺的类似物（benextramine，BXT，2），并分析了取代特异性结合的活性1 nM N- [丙酰-3H]神经肽Y（[3H] NPY）来自大鼠脑中对苯乙胺敏感的神经肽Y（NPY）结合位点。我们对这些类似物的新合成方法开始于，将胱胺与叔丁氧羰基（t-Boc）保护的6-氨基己酸的N-羟基琥珀酰亚胺酯酰化，然后用在二恶烷中的4 N HCl脱保护t-Boc基团。用适当取代的苯甲酸的N-羟基琥珀酰亚胺酯将该对称的二胺酰化，然后在回流的THF中用乙硼烷还原所得的四酰胺，得到目标化合物。缺乏苄基的BXT类似物（即化合物11）在浓度高达1.4 x 10（-3）M时没有[3H] NPY置换活性。邻位，间位和对位的活性范围是9倍在对苯达拉明敏感的NPY大鼠大脑结合位点的甲氧基，氯代和羟基苯达拉明类似物的区域异构体与在α-

  DOI：

  10.1021/jm00054a012

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-EGFR
  申请人：ABBVIE INC

  公开号：WO2017214282A1

  公开（公告）日：2017-12-14

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)

  本发明涉及抑制Bcl-xL的抗表皮生长因子受体（EGFR）抗体药物偶联物（ADCs），包括所述ADCs的组成和方法。公式（IIa），（IIb），（IIc）
• [EN] TRI-FUNCTIONAL CROSSLINKING REAGENTS<br/>[FR] RÉACTIFS DE RÉTICULATION TRIFONCTIONNELS
  申请人：ETH ZUERICH

  公开号：WO2017081069A1

  公开（公告）日：2017-05-18

  The present invention relates to tri-functional crosslinking reagents carrying (i) a ligand-reactive group for conjugation to a ligand of interest having at least one binding site on a target glycoprotein receptor, (ii) a hydrazone group for the capturing of oxidized receptor-glycoproteins and (iii) an affinity group selected from azides and aklynes for the detection, isolation and purification of captured glycoproteins; as well as their manufacturing. The invention further provides for improved methods of detecting, identifying and characterizing interactions between ligands and their corresponding target glycoproteins on living cells and in biological fluids. The invention further provides for new uses of catalysts in such methods.

  本发明涉及携带（i）与感兴趣的配体结合的配体反应性基团，该配体在目标糖蛋白受体上至少具有一个结合位点，（ii）用于捕获氧化受体-糖蛋白的缩醛基团，以及（iii）从叠氮化物和炔烃中选择的亲和基团，用于检测、分离和纯化捕获的糖蛋白的三功能交联试剂；以及它们的制造。本发明还提供了改进的方法，用于检测、识别和表征配体与其相应目标糖蛋白在活细胞和生物体液中的相互作用。本发明还提供了在这些方法中使用催化剂的新用途。
• [EN] BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME<br/>[FR] COMPOSÉS INHIBITEURS DE BCL XL AYANT UNE FAIBLE PERMÉABILITÉ CELLULAIRE ET CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT CEUX-CI
  申请人：ABBVIE INC

  公开号：WO2016094509A1

  公开（公告）日：2016-06-16

  The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

  本公开涉及具有低细胞渗透性的Bcl-xL抑制剂，包括这些抑制剂的抗体药物结合物（ADCs），用于合成ADCs的合成子，包括这些抑制剂或ADCs的组合物，以及使用这些抑制剂和ADCs的各种方法。